Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.
Brand: ZYPREXA
Published 2025-12-21 · Last reviewed 2025-12-28 · 5 references
Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.
Olanzapine (brand Zyprexa) is a second-generation antipsychotic (SGA) with broad efficacy across schizophrenia and bipolar disorder but notable metabolic adverse effects.
This profile focuses on adult and adolescent schizophrenia, bipolar I mania/mixed states, and bipolar depression in combination (Symbyax), while noting depot (Relprevv) REMS requirements.
The compare tool can help contrast metabolic risk, EPS profiles, and sedation when collaborating on antipsychotic selection.
The olanzapine evidence feed can support review, and long-acting injectable discussions can be routed through the LAI navigator when evaluating depot therapy.
Despite metabolic liabilities, olanzapine is favored for severe agitation, treatment-resistant schizophrenia, and sedation needs; weight gain, dyslipidemia, and glucose dysregulation make structured metabolic monitoring standard to reduce metabolic syndrome risk.
View labelExactRefer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.
Olanzapine antagonizes dopamine D1–D4 and serotonin 5-HT2A/5-HT2C receptors, moderating psychotic symptoms while influencing mood and cognition.
High affinity for histamine H1 and muscarinic receptors contributes to sedation and metabolic effects.
Olanzapine’s monitoring burden is primarily metabolic; documenting early lifestyle counseling and follow-up supports both clinical outcomes and coverage decisions.